Judge tries to broker treatment deal for patients with macular degeneration in funding rowBMJ 2008; 337 doi: http://dx.doi.org/10.1136/bmj.a864 (Published 16 July 2008) Cite this as: BMJ 2008;337:a864
- Clare Dyer
The judge presiding over a legal challenge to a primary care trust’s refusal to fund sight saving drugs on the NHS has adjourned the case in an attempt to broker a deal.
Mr Justice Forbes, sitting at the High Court in London, called on Novartis, manufacturer of ranibizumab (Lucentis), to try to work out an agreement with Warwickshire Primary Care Trust (PCT) so that the three patients who have brought the case to court can get the drug before their sight deteriorates further.
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial